# Flerie Invest

> Flerie Invest is a VC fund backing Biotechnology and Health Care. See 25 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 25
- Last investment: Mar 2026
- Lead investor: 48%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/flerie/
- Website: https://flerie.com/

Flerie Invest is a Europian investment firm that makes investments in the health care sector companies.

## Contacts

5 contacts available for Flerie Invest. Shizune tracks 2 team members at Flerie Invest. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/flerie-invest?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $2.5M–$23M |
| Series B | $12M–$75M |
| Venture - Series Unknown | $4.5M–$47M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 36% |
| Health Care | 8 | 32% |
| Pharmaceutical | 6 | 24% |
| Therapeutics | 4 | 16% |
| Medical | 3 | 12% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 24% |
| Venture - Series Unknown | 5 | 20% |
| Series B | 4 | 16% |
| Post-IPO Equity | 2 | 8% |
| Series D | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Sweden | 5 | 20% |
| United States | 2 | 8% |
| United Kingdom | 2 | 8% |
| The Netherlands | 2 | 8% |
| Israel | 1 | 4% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Thomas Eldered | Executive Chairman | 6 | https://shizune.co/investors/profile/thomas-eldered |
| Ted Fjällman | Partner | 5 | https://shizune.co/investors/profile/ted-fj%C3%A4llman |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nanologica | Nanologica combines unique know-how in the field of materials technology with a genuine interest in solving real problems in life science. The company works with nanoporous silica which has properties that are attractive in a wide variety of applications. In order to succeed, development work is carried out in close dialog with customers.Nanologica is unique in that it is a world leader in controlling the form, type of porosity and surface area of particles of silica. This competence can be used to produce particles that have the potential to solve problems in diverse application areas. The company’s core competency has been developed and expanded in twoareas of application in particular: drug delivery on the one hand and on the other chromatography, a technology used for the separation and purification of products on the market and in development.The starting point for Nanologica’s work is the material sciences, a field in which the company’s founder has developed and patented completely new materials. The initial research was based at Stockholm University and the Ångström laboratories atUppsala University. | $8.8M | Post-IPO Equity | Mar 26, 2026 |  |
| KAHR medical | KAHR Medical ("KAHR") is pioneering the development of "third generation biological drugs," a unique class of proprietary fusion-protein molecules with clear and far-reaching advantages. KAHR's technology represents a paradigm shift in protein-based pharmaceuticals that will significantly expand available treatment optionsfor cancer and autoimmune disorders. | $22M | Series B | Oct 15, 2025 |  |
| AnaCardio | AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. | $18.4M | Series A | Jan 09, 2025 |  |
| Vitara Biomedical | Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care. | $50M | Series B | Nov 18, 2024 |  |
| Microbiotica | Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models. |  | Venture - Series Unknown | Aug 27, 2024 |  |
| Synerkine Pharma | Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models. | $5.6M | Series A | Oct 12, 2023 |  |
| LipUm | Lipum aims to eliminate or alleviate painful symptoms for millions of patients suffering from chronic inflammatory diseases. Lipum has a biological anti-inflammatory drug candidate developed against Rheumatoid Arthritis (RA) – an autoimmune disease characterized by chronic inflammation of the joints. It often causes disability and lowers thequality of life for millions.Lipum also addresses the treatment of Juvenile Idiopathic Arthritis (JIA) that is a rare disease affecting children. A novel biological drug for this disease may be considered for an orphan drug designation. Treatment of other chronic inflammatory conditions is also explored. Related diseases are such as Crohn’s disease, ulcerative colitis, ankylosing spondylitis, and psoriatic arthritis.Lipum's biological anti-inflammatory drug candidate provides a novel mechanism of action. Therefore, it is assumed to have less adverse effects than current treatments in use. | $3.5M | Post-IPO Equity | Sep 22, 2022 |  |
| Vitara Biomedical | Vitara Biomedical has developed a therapeutic platform to support premature infants. Vitara Biomedical's platform was inspired by natural physiological processes to transform neonatal care. | $75M | Series B | Sep 13, 2022 |  |
| AnaCardio | AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. | $14M | Series A | Sep 07, 2022 |  |
| XNK Therapeutics | XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company has established a leadership position in the clinical development and manufacture of autologous NK cell-based products using its proprietary technology platform. Thecompany's platform technology and leading investigational drug candidate have ideal properties for targeting cancers, including settings where allogeneic cell products are not readily applicable. It is foreseen that the product will bring a critical component to tomorrow's cancer treatment strategies. XNK Therapeutics is headquartered in Stockholm, Sweden | $12.7M |  | Mar 29, 2022 |  |

10 of 25 investments shown.

## Co-investors
- [Korea Investment Partners](https://shizune.co/investors/profile/korea-investment-partners) — VC Fund, 5 deals together
- [Industrifonden](https://shizune.co/investors/profile/industrifonden) — VC Fund, 3 deals together
- [Mirae Asset Venture Investment](https://shizune.co/investors/profile/mirae-asset-venture-investment) — VC Fund, 3 deals together
- [Oriella Ltd.](https://shizune.co/investors/profile/oriella-ltd) — VC Fund, 3 deals together
- [Riyadh Valley Company](https://shizune.co/investors/profile/riyadh-valley-company) — VC Fund, 3 deals together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [New Business Venture Fund](https://shizune.co/investors/profile/new-business-venture-fund) — VC Fund
- [Frumtak Ventures](https://shizune.co/investors/profile/frumtak) — VC Fund
- [Brunnur Ventures](https://shizune.co/investors/profile/venture-capital-fund-brunnur) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Middle East](https://shizune.co/investors/medical-vc-funds-middle-east)
- [Medical VC Funds in Israel](https://shizune.co/investors/medical-vc-funds-israel)
- [Medical VC Funds in Sweden](https://shizune.co/investors/medical-vc-funds-sweden)
- [Biotechnology Investors in Middle East](https://shizune.co/investors/biotechnology-investors-middle-east)
- [Biotechnology VC Funds in Middle East](https://shizune.co/investors/biotechnology-vc-funds-middle-east)
- [Biotechnology Investors in Sweden](https://shizune.co/investors/biotechnology-investors-sweden)

## FAQ

### What does Flerie Invest invest in?

Flerie Invest invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Venture - Series Unknown stage. Most of the 25 investments tracked by Shizune back companies in Sweden. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Flerie Invest's check size?

Flerie Invest typically joins rounds of $2.5M–$23M at Series A, $12M–$75M at Series B and $4.5M–$47M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Flerie Invest participates in.

### How do I contact Flerie Invest?

Public channels for Flerie Invest include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Flerie Invest?

The team at Flerie Invest includes Thomas Eldered (Executive Chairman) and Ted Fjällman (Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co